Cellular biotechnology products and extracellular derivatives
Portfolio for clinical and institutional use. Each preparation is delivered with technical specifications, applicable controls and protocol integration advice.
Our production and release process
From source eligibility to released vial: SOP, traceability and cold chain, with predefined release criteria.
Source eligibility and screening
Selection according to criteria, consents and serology; case suitable for processing.
Laboratory processing
Isolation and expansion (cells) or purification (vesicles) under controlled conditions and traceability.
Characterization and release
Viability, identity/phenotype, sterility and endotoxins; in vesicles, particles and proteins; QA release.
Cryopreservation, documentation and delivery
Controlled freezing and storage; vial labeled with technical data sheet, traceability and, if applicable, certificate of quantification; cold chain shipment.
Our biotechnology products
Q-SUPPORT® DENTAL PULP STROMAL PRECURSORS
25 Million
50 Million
Mechanism and evidence
Paracrine and immunomodulation: secretion of extracellular factors and vesicles that modulate inflammation and stimulate tissue repair.
Odontogenic and osseous potential: capacity of differentiation towards lineages odontoblasto-like y osteogenicwith better performance when combined with biocompatible scaffolds.
Regenerative endodontics: evidence in development; experimental protocols with variable results.
Periodontics and implants: support in intrabony defects, alveolar ridge preservation y integration with biomaterials (early clinical phase).
Q-SUPPORT® NK (NATURAL KILLER)
25 Million
50 Million
Mechanism and evidence
Direct cytotoxicity: cell recognition with MHC-I low/absent and lysis by perforin/granzymes.
ADCC (CD16): synergy with monoclonal antibodiesdestroys cells opsonized with IgG.
Immunoregulation: secretion of IFN-γ/TNF-α y crosstalk with dendritic and Tadjusting the tumor microenvironment.
Evidence framework: mechanisms valid in basic immunology; ongoing clinical translationwith response influenced by patient status, KIR/HLA profile and degree of activation ex vivo.
Q-SUPPORT® EXOSOMES
1,550 µg per vial of 5 mL
Mechanism and evidence
They act as natural mediators of cellular communication, transferring proteins, RNA and bioactive factors that modulate the inflammatory response and stimulate endogenous regeneration mechanisms.
Promote the controlled angiogenesisthe reorganization of the extracellular matrix and the functional recovery of tissuereducing variability in clinical outcomes and return-to-work times.
Developed for scenarios where predictable recovery, pain reduction y sustained tissue stability during follow-up.
Q-SUPPORT® STROMAL PRECURSORS
10 Million
25 Million
50 Million
Mechanism and evidence
Paracrine and immunomodulation: factors and EV that adjust inflammation and promote repair.
Odontogenic/bony potential: differentiation odontoblast-like and bone; better performance with scaffolding adequate.
Regenerative endodontics: evolving protocols; results heterogeneous between studies.
Periodontium/implants: support in intrabony defects and ridge preservation (early evidence).